News | May 21, 2015

Amaranth Medical Reports Data for Two FORTITUDE Bioresorbable Scaffold Studies at EuroPCR 2015

Device has, to date, navigated complex anatomies with no peri-procedural complications

Amaranth Medical, Fortitude BRS, MEND-II, RENASCENT, EuroPCR 2015

Image courtesy of Amaranth Medical

May 18, 2015 — Amaranth Medical announced plans to report clinical results from the company's ongoing trial of its second-generation Fortitude sirolimus-eluting bioresorbable scaffold (BRS) at EuroPCR 2015. Juan F. Granada, M.D., executive director and chief innovation officer of the CRF-Skirball Center for Innovation (SCI), will present these updates.

The Fortitude sirolimus-eluting BRS is being evaluated in two multi-center, international trials, both of which are designed to support a planned application for CE Mark. In this clinical program, a total 49 patients have been treated in centers in Colombia, South America (MEND-II trial) and Italy (RENASCENT trial). Early preliminary results from these studies demonstrate the scaffold's capabilities to navigate through complex anatomies with a balance of deliverability and biomechanical performance. No peri-procedural complications have been reported to date.

"Our clinical trial experience with the Fortitude BRS is very encouraging," commented Granada, primary investigator of the MEND-II study. "Building upon its high biocompatibility profile, the Fortitude BRS exhibits the biomechanical behavior expected by the interventional community in addition to the long-term vascular benefits of device absorption, both of which have significant impact on clinical outcomes. Specifically, the Fortitude BRS has the capability to over-expand approximately four-fold what is possible with commercially available BRS, providing physicians with the operational flexibility we have with metallic scaffolds."

Antonio Colombo, M.D., director of the cardiac cath lab and interventional cardiology unit, EMO-GVM Centro Cuore Columbus in Milan, Italy, and primary investigator of the RENASCENT trial, added, "While results from the RENASCENT study are still early, we are encouraged by the acute performance of the device, which shows no indication of device failure or peri-procedural complications, further supporting the mechanical strength and durability of the device platform. I look forward to enrolling additional patients and completing nine?month imaging follow-up visits, which will unveil the real potential of this second-generation BRS platform."

Additional details of Amaranth's technology clinical program will be provided by Granada in a presentation titled: "Bench Testing and Pre-Clinical Evaluation of the Amaranth PLLA Scaffold."

The MEND-II and RENASCENT trials are built upon the successful results from MEND-I, the first-in-human clinical study of Amaranth's bare Fortitude BRS, which was conducted in Colombia, South America. This study met its primary endpoint at six months. Patients who had been enrolled in MEND-I continue to show excellent clinical performance two years after implant. Further, angiographic and optical coherence tomography (OCT) follow-up demonstrate late lumen gain in treated vessels at two years, relative to six months.

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init